Literature DB >> 18080036

The mTOR pathway as a potential target for the development of therapies against neurological disease.

Daniel Zemke1, Seema Azhar, Arshad Majid.   

Abstract

The mammalian target of rapamycin (mTOR) is a protein tyrosine kinase that regulates cell proliferation and survival via its effects on transcription, translation and autophagy. The activity of mTOR is controlled by a number of nutrient and energy sensing pathways, inhibiting cell proliferation under conditions of deprivation. In addition, mTOR has been associated with the inhibition of apoptosis and the clearance of toxic protein aggregates. Many neurodegenerative diseases are characterized by neuronal death via apoptosis, and it is possible that modulation of mTOR activity may offer some protection against their effects. In particular, diseases involving oxygen and nutrient deprivation, such as stroke, or diseases characterized by aggregate formation, such as Alzheimer's and Huntington's disease, could gain substantial benefit by either inhibiting or enhancing mTOR activity. In addition, inhibition of mTOR in cancerous tissue decreases cell proliferation and increases apoptosis, and is an effective therapy for brain tumors. In this article, the effects of mTOR and their potential usefulness for the treatment of neurological disease are examined. (c) 2007 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18080036     DOI: 10.1358/dnp.2007.20.8.1157618

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  18 in total

Review 1.  Dietary interventions to extend life span and health span based on calorie restriction.

Authors:  Robin K Minor; Joanne S Allard; Caitlin M Younts; Theresa M Ward; Rafael de Cabo
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-04-06       Impact factor: 6.053

Review 2.  Bioenergetic medicine.

Authors:  Russell H Swerdlow
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

3.  α-Endosulfine (ARPP-19e) Expression in a Rat Model of Stroke.

Authors:  Rupal I Mehta; Natalia Tsymbalyuk; Svetlana Ivanova; Jesse A Stokum; Kyoon Woo; Volodymyr Gerzanich; J M Simard
Journal:  J Neuropathol Exp Neurol       Date:  2017-10-01       Impact factor: 3.685

Review 4.  Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.

Authors:  Russell H Swerdlow
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

5.  Beneficial effect of Sparassis crispa on stroke through activation of Akt/eNOS pathway in brain of SHRSP.

Authors:  Hisae Yoshitomi; Emiko Iwaoka; Masahide Kubo; Masaru Shibata; Ming Gao
Journal:  J Nat Med       Date:  2010-11-13       Impact factor: 2.343

Review 6.  Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

7.  Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination.

Authors:  S Priyadarshini Narayanan; Ana I Flores; Feng Wang; Wendy B Macklin
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167

8.  4E-BP1 Protects Neurons from Misfolded Protein Stress and Parkinson's Disease Toxicity by Inducing the Mitochondrial Unfolded Protein Response.

Authors:  Somasish Ghosh Dastidar; Michael T Pham; Matthew B Mitchell; Steven G Yeom; Sarah Jordan; Angela Chang; Bryce L Sopher; Albert R La Spada
Journal:  J Neurosci       Date:  2020-10-12       Impact factor: 6.167

Review 9.  Dysfunctions of neuronal and glial intermediate filaments in disease.

Authors:  Ronald K H Liem; Albee Messing
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

10.  Human disease-drug network based on genomic expression profiles.

Authors:  Guanghui Hu; Pankaj Agarwal
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.